QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NYSE:NVTA

Invitae (NVTA) Stock Forecast, Price & News

$0.61
-0.02 (-3.19%)
(As of 09/28/2023 ET)
Compare
Today's Range
$0.60
$0.65
50-Day Range
$0.61
$1.45
52-Week Range
$0.60
$3.78
Volume
9.30 million shs
Average Volume
8.89 million shs
Market Capitalization
$162.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.08

Invitae MarketRank™ Forecast

Analyst Rating
Strong Sell
1.40 Rating Score
Upside/​Downside
241.6% Upside
$2.08 Price Target
Short Interest
Bearish
16.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.14
Upright™ Environmental Score
News Sentiment
0.22mentions of Invitae in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.41) to ($1.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

781st out of 969 stocks

Medical Laboratories Industry

20th out of 25 stocks


NVTA stock logo

About Invitae (NYSE:NVTA) Stock

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

NVTA Price History

NVTA Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Invitae Stock Analysis: Buy, Sell, or Hold?
Invitae (NYSE:NVTA) Downgraded to Sell at StockNews.com
Brokerages Set Invitae Co. (NYSE:NVTA) PT at $2.08
Cathie Wood Is Betting on This Struggling Stock. Should You?
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Why Invitae Stock Is Crashing Today
Down 96%, Is Invitae Stock a Buy?
Invitae (NVTA) Q2 2023 Earnings Call Transcript
Invitae Reports Second Quarter 2023 Financial Results
Invitae (NVTA) Upgraded to Buy: Here's Why
Invitae Corporation Common Stock (NVTA)
See More Headlines
Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Company Calendar

Last Earnings
8/08/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.08
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+230.2%
Consensus Rating
Strong Sell
Rating Score (0-4)
1.40
Research Coverage
5 Analysts

Profitability

Net Income
$-3,106,290,000.00
Net Margins
-161.92%
Pretax Margin
-163.60%

Debt

Sales & Book Value

Annual Sales
$516.30 million
Cash Flow
$7.86 per share
Book Value
$0.42 per share

Miscellaneous

Free Float
265,038,000
Market Cap
$167.79 million
Optionable
Optionable
Beta
1.70
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Randal W. Scott Ph.D. (Age 65)
    Co-Founder & Chairman
    Comp: $50k
  • Mr. Kenneth D. Knight (Age 62)
    Pres, CEO & Director
    Comp: $1.4M
  • Mr. Thomas R. BridaMr. Thomas R. Brida (Age 52)
    Gen. Counsel, Chief Compliance Officer & Sec.
    Comp: $776.72k
  • Mr. Robert Dickey IV (Age 67)
    M.B.A., Interim Chief Financial Officer
  • Mr. Jeffrey Parsons (Age 63)
    Interim Chief Accounting Officer
  • Ms. Hoki Luk (Age 47)
    Head of Investor Relations and Capital Markets
  • Ms. Shelly D. GuyerMs. Shelly D. Guyer (Age 63)
    Chief Sustainability Officer
  • Ms. Desarie French
    Chief Talent Officer
  • Dr. W. Michael Korn M.D.
    Chief Medical Officer
  • Mr. Jackson J. Finks C.F.A.
    CFA, Director of Investor Relations & Strategic Fin.













NVTA Stock - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong sell" NVTA shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price forecast for 2023?

5 equities research analysts have issued 12-month target prices for Invitae's stock. Their NVTA share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $2.08 in the next twelve months. This suggests a possible upside of 230.2% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2023?

Invitae's stock was trading at $1.86 at the beginning of the year. Since then, NVTA stock has decreased by 66.2% and is now trading at $0.6284.
View the best growth stocks for 2023 here
.

Are investors shorting Invitae?

Invitae saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 39,310,000 shares, a drop of 32.9% from the August 15th total of 58,580,000 shares. Based on an average daily volume of 9,660,000 shares, the short-interest ratio is currently 4.1 days.
View Invitae's Short Interest
.

When is Invitae's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NVTA earnings forecast
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) issued its earnings results on Tuesday, August, 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. The medical research company earned $120.53 million during the quarter, compared to analysts' expectations of $121.19 million. Invitae had a negative net margin of 161.92% and a negative trailing twelve-month return on equity of 6,100.71%.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480.00 million-$500.00 million, compared to the consensus revenue estimate of $497.62 million.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.38%), BlackRock Inc. (7.99%), Sumitomo Mitsui Trust Holdings Inc. (6.49%), State Street Corp (2.84%), Geode Capital Management LLC (1.80%) and Northern Trust Corp (0.82%). Insiders that own company stock include Artur Bergman, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $0.63.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $167.79 million and generates $516.30 million in revenue each year. The medical research company earns $-3,106,290,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis.

How many employees does Invitae have?

The company employs 1,700 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -